Cidara Therapeutics Inc (CDTX) Just Recorded A Sigfniciant Increase

September 4, 2017 - By Adrian Mccoy

The stock of Cidara Therapeutics Inc (NASDAQ:CDTX) is a huge mover today! The stock increased 4.35% or $0.3 on September 1, reaching $7.2. About 64,757 shares traded. Cidara Therapeutics Inc (NASDAQ:CDTX) has declined 38.96% since September 4, 2016 and is downtrending. It has underperformed by 55.66% the S&P500.
The move comes after 9 months positive chart setup for the $121.41M company. It was reported on Sep, 4 by Barchart.com. We have $7.70 PT which if reached, will make NASDAQ:CDTX worth $8.50M more.

Cidara Therapeutics Inc (NASDAQ:CDTX) Ratings Coverage

Among 5 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cidara Therapeutics had 10 analyst reports since October 9, 2015 according to SRatingsIntel. WBB Securities upgraded Cidara Therapeutics Inc (NASDAQ:CDTX) on Friday, August 11 to “Hold” rating. The firm has “Sell” rating given on Friday, July 28 by WBB Securities. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, August 10. H.C. Wainwright initiated the shares of CDTX in report on Monday, December 19 with “Buy” rating. WBB Securities upgraded Cidara Therapeutics Inc (NASDAQ:CDTX) rating on Friday, October 9. WBB Securities has “Hold” rating and $13 target. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, June 23 report. The stock has “Outperform” rating by Leerink Swann on Wednesday, December 21. The stock of Cidara Therapeutics Inc (NASDAQ:CDTX) earned “Buy” rating by Cantor Fitzgerald on Monday, June 5. The rating was downgraded by WBB Securities to “Sell” on Friday, September 23.

More notable recent Cidara Therapeutics Inc (NASDAQ:CDTX) news were published by: Globenewswire.com which released: “Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results” on May 10, 2017, also Businesswire.com with their article: “Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance …” published on March 30, 2017, Businesswire.com published: “Cidara Therapeutics Announces Promotion of Taylor Sandison, MD, MPH, to Chief …” on April 25, 2017. More interesting news about Cidara Therapeutics Inc (NASDAQ:CDTX) were released by: Businesswire.com and their article: “Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22” published on May 30, 2017 as well as Businesswire.com‘s news article titled: “Cidara Therapeutics Announces Publication of Results from In Vivo Study …” with publication date: August 01, 2017.

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The company has market cap of $121.41 million. The Firm is engaged in the discovery, development and commercialization of anti-infectives. It currently has negative earnings. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.